NASDAQ: CBAY

Gilead Sciences (NASDAQ: GILD) has moved one step closer to finalizing its cash tender offer for the acquisition of fellow US company CymaBay Therapeutics (NASDAQ: CBAY), following the expiration of a mandatory waiting period under local laws last week. The two companies had previously submitted regulatory filings for approval of…